专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008057172A2 ORGANIC COMPOUNDS 审中-公开
标题翻译：有机化合物
公开(公告)号：WO2008057172A2
公开(公告)日：2008-05-15
申请号：PCT/US2007022125
申请日：2007-10-17
申请人： NOVARTIS AG , GAITHER LARRY ALEXANDER , IOURGENKO VADIM , LABOW MARK ARON , PORTER DALE ALAN , STRAUB CHRISTOPHER SEAN , YAO YAO , ZAWEL LEIGH
发明人： GAITHER LARRY ALEXANDER , IOURGENKO VADIM , LABOW MARK ARON , PORTER DALE ALAN , STRAUB CHRISTOPHER SEAN , YAO YAO , ZAWEL LEIGH
IPC分类号： G01N33/50
CPC分类号： G01N33/574 , G01N33/6869 , G01N2333/525
摘要： A method to predict which patients will respond to a IAP inhibiting compound comprising: a) administering an IAP inhibitor compound to a patient, and b) measuring TNF-a or IL-8 levels.
摘要翻译：预测哪些患者将对IAP抑制化合物起反应的方法，包括：a）向患者施用IAP抑制剂化合物，和b）测量TNF-α或IL-8水平。

2. 发明申请

WO2007040550A3 TORC POLYNUCLEOTIDES AND POLYPEPTIDES, AND METHODS OF USE 审中-公开
标题翻译： TORC多核苷酸和多肽，以及使用方法
公开(公告)号：WO2007040550A3
公开(公告)日：2007-06-28
申请号：PCT/US2005038207
申请日：2005-10-24
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , BITTINGER MARK , LABOW MARK ARON
发明人： BITTINGER MARK , LABOW MARK ARON
IPC分类号： C07K14/47 , A61K38/00 , A61K39/395
CPC分类号： C07K14/4705 , A61K38/00 , G01N33/5008 , G01N33/5035 , G01N33/5091 , G01N2333/4706
摘要： The present invention relates to a broad range of methods that utilize a transducer of regulated CREB (TORC)-related polynucleotide, polypeptide, or TORC-specific antibody. In addition the invention relates to TORC-related polynucleotide, polypeptide, or TORC-specific antibody compositions, including variants of TORC wild-type sequences. Exemplary methods include a method of stimulating a TORC related process in a cell as well as a method of inhibiting a TORC-related process in a cell, and a method of inhibiting TORC-related processes in a cell. The invention additionally disclosed therapeutic methods of substantially inhibiting the development of, treating, or ameliorating a disease or pathological condition in a subject related to an abnormal level of a TORC-activated process in a cell that includes administering one or more therapeutically effective doses to the subject of either a substance that modulates accumulation of a TORC polypeptide in a subcellular region of the cell, or of a substance that inhibits expression of a TORC polypeptide in the cell. In an additional aspect a method of identifying an agent that modulates the activity of a TORC-related process in a cell is disclosed. In still a further aspect the invention relates to a method of detecting the presence or quantifying the amount of a TORC polypeptide in a sample. In a further aspect, a method is disclosed of determining whether the amount of a TORC polypeptide in a sample differs from the amount of the TORC polypeptide in a reference. An additional aspect relates to a method of contributing to the diagnosis or prognosis of, or to developing a therapeutic strategy for, a disease or pathology in a first subject, wherein the subcellular localization of a TORC polypeptide in the pathology is known to differ from the subcellular localization of the TORC polypeptide in a nonpathological state.
摘要翻译：本发明涉及利用受调节的CREB（TORC）相关多核苷酸，多肽或TORC特异性抗体的转导子的广泛范围的方法。此外，本发明涉及TORC相关多核苷酸，多肽或TORC特异性抗体组合物，包括TORC野生型序列的变体。示例性方法包括刺激细胞中TORC相关过程的方法以及抑制细胞中TORC相关过程的方法，以及抑制细胞中TORC相关过程的方法。本发明另外公开了治疗方法，其基本上抑制与细胞中TORC活化过程的异常水平相关的受试者的疾病或病理状态的发展，治疗或改善，其包括向所述细胞施用一种或多种治疗有效剂量调节细胞亚细胞区域中TORC多肽的积累的物质或抑制细胞中TORC多肽表达的物质的受试者。在另一方面，公开了一种识别调节细胞中TORC相关过程的活性的试剂的方法。在另一方面，本发明涉及检测样品中TORC多肽的存在或定量的方法。在另一方面，公开了确定样品中TORC多肽的量是否与参考文献中TORC多肽的量不同的方法。另一方面涉及有助于诊断或预后的方法，或用于制定第一受试者的疾病或病理学的治疗策略，其中TORC多肽在病理学中的亚细胞定位已知不同于 TORC多肽在非病理状态下的亚细胞定位。

3. 发明申请

WO2010034758A3 dsRNA FOR TREATING VIRAL INFECTION 审中-公开
标题翻译： dsRNA用于治疗病毒感染
公开(公告)号：WO2010034758A3
公开(公告)日：2010-08-26
申请号：PCT/EP2009062347
申请日：2009-09-23
申请人： NOVARTIS AG , BORAWSKI JASON , GAITHER LARRY ALEXANDER , LABOW MARK ARON
发明人： BORAWSKI JASON , GAITHER LARRY ALEXANDER , LABOW MARK ARON
IPC分类号： C12N15/113 , A61K31/713 , A61P31/14
CPC分类号： C12N15/1137 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to double-stranded ribonucleic acids (dsRNAs) targeting gene expression carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD), and their use for treating infection by positive stranded RNA viruses such as hepatitis C virus (HCV). Each dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the CAD target mRNA. A plurality of such dsRNA may be employed to provide therapeutic benefit. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, and including a delivery modality such as fully encapsulated liposomes or lipid complexes. The invention further includes methods for treating diseases caused by positive stranded RNA virus infection using the pharmaceutical compositions; and methods for inhibiting the propogation of positive stranded RNA viruses in and between cells.
摘要翻译：本发明涉及靶向基因表达氨基甲酰磷酸合成酶2，天冬氨酸转氨甲酰酶和二氢激酶（CAD）的双链核糖核酸（dsRNA）及其用于治疗由正链RNA病毒如丙型肝炎病毒（HCV）感染的用途。每个dsRNA包含具有长度小于30个核苷酸的核苷酸序列的反义链，其长度通常为19-25个核苷酸，并且其与至少一部分CAD靶mRNA基本互补。可以使用多种这样的dsRNA来提供治疗益处。本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物，并且包括递送方式如完全包封的脂质体或脂质复合物。本发明还包括使用药物组合物治疗由正链RNA病毒感染引起的疾病的方法; 以及用于抑制细胞内和细胞内的正链RNA病毒传播的方法。

4. 发明申请

WO2010046401A1 METHODS OF USING MEVALONATE DECARBOXYLASE (MVD) ANTAGONISTS 审中-公开
标题翻译：使用甲醛脱羧酶（MVD）拮抗剂的方法
公开(公告)号：WO2010046401A1
公开(公告)日：2010-04-29
申请号：PCT/EP2009/063816
申请日：2009-10-21
申请人： NOVARTIS AG , BORAWSKI, Jason , GAITHER, Larry Alexander , LABOW, Mark Aron
发明人： BORAWSKI, Jason , GAITHER, Larry Alexander , LABOW, Mark Aron
IPC分类号： A61K31/366 , A61K31/7088 , A61P31/14 , C12N9/88
CPC分类号： C12N9/88 , C12N15/1137 , C12N2310/14 , C12Y401/01033
摘要： The present invention provides novel methods of reducing Flavivirus viral replication and/or infection, e.g., Dengue virus. The invention employs mevalonate decarboxylase (MVD) antagonists to inhibit the cholesterol biosynthesis pathway, thereby inhibiting viral replication / infection.
摘要翻译：本发明提供了减少黄病毒病毒复制和/或感染的新方法，例如登革热病毒。本发明使用甲羟戊酸脱羧酶（MVD）拮抗剂抑制胆固醇生物合成途径，从而抑制病毒复制/感染。

5. 发明申请

WO2008057172A3 ORGANIC COMPOUNDS 审中-公开
公开(公告)号：WO2008057172A3
公开(公告)日：2008-05-15
申请号：PCT/US2007/022125
申请日：2007-10-17
申请人： NOVARTIS AG , GAITHER, Larry, Alexander , IOURGENKO, Vadim , LABOW, Mark, Aron , PORTER, Dale, Alan , STRAUB, Christopher, Sean , YAO, Yao , ZAWEL, Leigh
发明人： GAITHER, Larry, Alexander , IOURGENKO, Vadim , LABOW, Mark, Aron , PORTER, Dale, Alan , STRAUB, Christopher, Sean , YAO, Yao , ZAWEL, Leigh
IPC分类号： G01N33/574 , G01N33/68
摘要： A method to predict which patients will respond to a IAP inhibiting compound comprising: a) administering an IAP inhibitor compound to a patient, and b) measuring TNF-α or IL-8 levels.

6. 发明申请

WO2009004085A3 DSRNA FOR TREATING VIRAL INFECTION 审中-公开
标题翻译：用于治疗病毒感染的DSRNA
公开(公告)号：WO2009004085A3
公开(公告)日：2009-08-06
申请号：PCT/EP2008058706
申请日：2008-07-04
申请人： NOVARTIS AG , LABOW MARK ARON , GAITHER LARRY ALEXANDER , BORAWSKI JASON
发明人： LABOW MARK ARON , GAITHER LARRY ALEXANDER , BORAWSKI JASON
IPC分类号： A61K31/713 , C12N15/113
CPC分类号： C12N15/1137 , A61K31/713 , C12N2310/14 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3233 , C12N2310/3515 , C12N2310/531 , C12N2310/3521
摘要： The invention relates to double-stranded ribonucleic acids (dsRNAs) targeting gene expression of phosphatidylinositol 4-kinase (PI4K), in particular human phosphatidylinositol 4-kinase, catalytic, beta polypeptide (PIK4CB) or human phosphatidylinositol 4-kinase, catalytic, alpha polypeptide (PIK4CA), and their use for treating infection by positive stranded RNA viruses such as hepatitis C virus (HCV). Each dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PIK4CB or PIK4CA target mRNA. A plurality of such dsRNA may be employed to provide therapeutic benefit. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, and including a delivery modality such as fully encapsulated liposomes or lipid complexes.
摘要翻译：本发明涉及靶向磷脂酰肌醇4-激酶（PI4K）的基因表达的双链核糖核酸（dsRNA），特别是人磷脂酰肌醇4-激酶，催化的β多肽（PIK4CB）或人磷脂酰肌醇4-激酶，催化的α多肽（PIK4CA），以及它们用于治疗由正链RNA病毒如丙型肝炎病毒（HCV）感染的用途。每个dsRNA包含具有长度小于30个核苷酸的核苷酸序列的反义链，其长度通常为19-25个核苷酸，并且其与至少一部分PIK4CB或PIK4CA靶mRNA基本上互补。可以使用多种这样的dsRNA来提供治疗益处。本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物，并且包括递送方式如完全包封的脂质体或脂质复合物。

7. 发明申请

WO2007040550A2 TORC POLYNUCLEOTIDES AND POLYPEPTIDES, AND METHODS OF USE 审中-公开
标题翻译： TORC多核苷酸和多肽及其使用方法
公开(公告)号：WO2007040550A2
公开(公告)日：2007-04-12
申请号：PCT/US2005/038207
申请日：2005-10-24
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , BITTINGER, Mark , LABOW, Mark, Aron
发明人： BITTINGER, Mark , LABOW, Mark, Aron
IPC分类号： C07K14/435
CPC分类号： C07K14/4705 , A61K38/00 , G01N33/5008 , G01N33/5035 , G01N33/5091 , G01N2333/4706
摘要： The present invention relates to a broad range of methods that utilize a transducer of regulated CREB (TORC)-related polynucleotide, polypeptide, or TORC-specific antibody. In addition the invention relates to TORC-related polynucleotide, polypeptide, or TORC-specific antibody compositions, including variants of TORC wild-type sequences. Exemplary methods include a method of stimulating a TORC related process in a cell as well as a method of inhibiting a TORC-related process in a cell, and a method of inhibiting TORC-related processes in a cell. The invention additionally disclosed therapeutic methods of substantially inhibiting the development of, treating, or ameliorating a disease or pathological condition in a subject related to an abnormal level of a TORC-activated process in a cell that includes administering one or more therapeutically effective doses to the subject of either a substance that modulates accumulation of a TORC polypeptide in a subcellular region of the cell, or of a substance that inhibits expression of a TORC polypeptide in the cell. In an additional aspect a method of identifying an agent that modulates the activity of a TORC-related process in a cell is disclosed. In still a further aspect the invention relates to a method of detecting the presence or quantifying the amount of a TORC polypeptide in a sample. In a further aspect, a method is disclosed of determining whether the amount of a TORC polypeptide in a sample differs from the amount of the TORC polypeptide in a reference. An additional aspect relates to a method of contributing to the diagnosis or prognosis of, or to developing a therapeutic strategy for, a disease or pathology in a first subject, wherein the subcellular localization of a TORC polypeptide in the pathology is known to differ from the subcellular localization of the TORC polypeptide in a nonpathological state.
摘要翻译：本发明涉及利用受调节的CREB（TORC）相关多核苷酸，多肽或TORC特异性抗体的换能器的广泛范围的方法。另外，本发明涉及TORC相关多核苷酸，多肽或TORC特异性抗体组合物，包括TORC野生型序列的变体。示例性方法包括刺激细胞中TORC相关过程的方法以及抑制细胞中TORC相关过程的方法以及抑制细胞中TORC相关过程的方法。本发明另外公开了基本上抑制与细胞中TORC激活过程的异常水平相关的受试者中疾病或病理状态的发展，治疗或改善的治疗方法，所述方法包括对所述受试者施用一种或多种治疗有效剂量受试者是调节TORC多肽在细胞亚细胞区积累的物质或抑制细胞中TORC多肽表达的物质的受试者。在另一方面，公开了鉴定调节细胞中TORC相关过程的活性的试剂的方法。在又一方面，本发明涉及检测样品中TORC多肽的存在或定量的方法。另一方面，公开了确定样品中TORC多肽的量与参考中TORC多肽的量是否不同的方法。另一方面涉及有助于第一受试者的疾病或病理的诊断或预后或制定治疗策略的方法，其中病理学中TORC多肽的亚细胞定位已知不同于 TORC多肽在非病理状态下的亚细胞定位。

8. 发明申请

WO2004085646A1 CYCLIC AMP RESPONSE ELEMENT ACTIVATOR PROTEINS AND USES RELATED THERETO 审中-公开
标题翻译：循环AMP反应元件激活蛋白及其相关用途
公开(公告)号：WO2004085646A1
公开(公告)日：2004-10-07
申请号：PCT/EP2004/003182
申请日：2004-03-25
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , IOURGENKO, Vadim , LABOW, Mark, Aron , SONG, Chuanzheng , ZHANG, Wenjun , ZHU, Jian
发明人： IOURGENKO, Vadim , LABOW, Mark, Aron , SONG, Chuanzheng , ZHANG, Wenjun , ZHU, Jian
IPC分类号： C12N15/12
CPC分类号： A61K38/1709 , C07K14/4705 , C12Q1/6883 , C12Q2600/158 , G01N2500/00
摘要： The invention discloses newly identified cyclic AMP response element activator proteins (CREAP proteins). It is contemplated herein that said proteins are suitable drug targets for the development of new therapeutics to prevent, treat or ameliorate pathological conditions related to abnormal activation of CRE-dependent gene expression or abnormal activation of chemokines. The invention relates to methods to prevent, treat or ameliorate said pathological conditions and pharmaceutical compositions therefor comprising modulators with inhibitory effect on CREAP protein activity and/or CREAP gene expression. The invention also relates to methods to identify compounds with therapeutic usefulness to treat said pathological conditions, comprising identifying compounds that can inhibit CREAP protein activity and/or CREAP gene expression.
摘要翻译：本发明公开了新鉴定的环AMP应答元件活化蛋白（CREAP蛋白）。本文预期所述蛋白质是用于开发新的治疗剂以预防，治疗或改善与CRE依赖性基因表达异常活化或趋化因子异常激活相关的病理状况的合适药物靶标。本发明涉及预防，治疗或改善所述病理状态的方法及其药物组合物，其包含对CREAP蛋白活性和/或CREAP基因表达具有抑制作用的调节剂。本发明还涉及鉴定具有治疗所述病理状况的治疗有效性的化合物的方法，其包括鉴定能抑制CREAP蛋白活性和/或CREAP基因表达的化合物。

9. 发明申请

WO2009004085A2 DSRNA FOR TREATING VIRAL INFECTION 审中-公开
标题翻译：用于治疗病毒感染的DSRNA
公开(公告)号：WO2009004085A2
公开(公告)日：2009-01-08
申请号：PCT/EP2008/058706
申请日：2008-07-04
申请人： NOVARTIS AG , LABOW, Mark Aron , GAITHER, Larry Alexander , BORAWSKI, Jason
发明人： LABOW, Mark Aron , GAITHER, Larry Alexander , BORAWSKI, Jason
IPC分类号： C12N15/11 , A61K31/713 , C07H21/00
CPC分类号： C12N15/1137 , A61K31/713 , C12N2310/14 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3233 , C12N2310/3515 , C12N2310/531 , Y02A50/385 , C12N2310/3521
摘要： The invention relates to double-stranded ribonucleic acids (dsRNAs) targeting gene expression of phosphatidylinositol 4-kinase (PI4K), in particular human phosphatidylinositol 4- kinase, catalytic, beta polypeptide (PIK4CB) or human phosphatidylinositol 4-kinase, catalytic, alpha polypeptide (PIK4CA), and their use for treating infection by positive stranded RNA viruses such as hepatitis C virus (HCV). Each dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PIK4CB or PIK4CA target mRNA. A plurality of such dsRNA may be employed to provide therapeutic benefit. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, and including a delivery modality such as fully encapsulated liposomes or lipid complexes. The invention further includes methods for treating diseases caused by positive stranded RNA virus infection using the pharmaceutical compositions; and methods for inhibiting the propogation of positive stranded RNA viruses in and between cells.
摘要翻译：本发明涉及靶向磷脂酰肌醇4-激酶（PI4K）的基因表达的双链核糖核酸（dsRNA），特别是人磷脂酰肌醇4-激酶，催化的β多肽（PIK4CB）或人磷脂酰肌醇4-激酶，催化的α多肽（PIK4CA），以及它们用于治疗由正链RNA病毒如丙型肝炎病毒（HCV）感染的用途。每个dsRNA包含具有长度小于30个核苷酸的核苷酸序列的反义链，其长度通常为19-25个核苷酸，并且其与至少一部分PIK4CB或PIK4CA靶mRNA基本上互补。可以使用多种这样的dsRNA来提供治疗益处。本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物，并且包括递送方式如完全包封的脂质体或脂质复合物。本发明还包括使用药物组合物治疗由正链RNA病毒感染引起的疾病的方法; 以及用于抑制细胞内和细胞内的正链RNA病毒传播的方法。

10. 发明申请

WO2006044366A3 E2-EPF5, A NOVEL THERAPEUTIC PROTEIN AND TARGET 审中-公开
标题翻译： E2-EPF5，一种新的治疗蛋白质和目标
公开(公告)号：WO2006044366A3
公开(公告)日：2007-01-04
申请号：PCT/US2005036505
申请日：2005-10-12
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , ASSELBERGS FRED A , HALL JONATHAN , HUESKEN DIETER , LABOW MARK ARON , MICKANIN CRAIG STEPHEN , SCHMID PETER , WEILER JAN , WYDER LORENZA
发明人： ASSELBERGS FRED A , HALL JONATHAN , HUESKEN DIETER , LABOW MARK ARON , MICKANIN CRAIG STEPHEN , SCHMID PETER , WEILER JAN , WYDER LORENZA
IPC分类号： A61K39/395 , G01N33/50
CPC分类号： C12N15/1137 , C07K16/40 , C12N2310/11 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12Y603/02019 , C12N2310/3525
摘要： The present invention relates to novel uses for ubiquitin conjugating enzyme E2-EPF5. In particular, inhibition of E2-EPF5 activity is shown to reduce the production VEGF, as well as other proteins regulated the transcription factor HIF-1, in response to hypoxia. Based on these findings the present invention provides therapeutic methods and pharmaceutical compositions useful for the treatment of diseases related VEGF induced angiogenesis. In addition, E2-EPF5 is provided as target for the development of therapeutics. Accordingly, the invention provides screening methods for identifying candidate compounds that inhibit E2-EPF5 activity and may therefore be used to treat VEGF induced angiogenesis such as tumor related angiogenesis. Finally, the invention also provides methods for the inhibition of VEGF and other HIF-1 regulated proteins.
摘要翻译：本发明涉及泛素缀合酶E2-EPF5的新用途。特别地，E2-EPF5活性的抑制显示可以减少VEGF的产生，以及调节转录因子HIF-1的其他蛋白质，以应对缺氧。基于这些发现，本发明提供治疗方法和药物组合物，其可用于治疗与VEGF相关的VEGF诱导的血管生成。此外，提供E2-EPF5作为治疗开发的目标。因此，本发明提供了用于鉴定抑制E2-EPF5活性的候选化合物的筛选方法，因此可用于治疗VEGF诱导的血管发生如肿瘤相关的血管发生。最后，本发明还提供了抑制VEGF和其他HIF-1调节蛋白的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式